Company news
Edesa Biotech, Inc. (NASDAQ:EDSA) news
Edesa Biotech, Inc. news releases on 6ix. Latest, Aug 19, 2026: Edesa Biotech Announces Proposed Public Offering
Press releases & updates
Edesa Biotech Announces Proposed Public Offering
August 19, 2026
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
August 18, 2026
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
August 13, 2026
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
June 11, 2026
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
June 4, 2026
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
May 18, 2026
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
May 14, 2026
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
March 31, 2026
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
March 25, 2026
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
February 24, 2026
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
February 13, 2026
Edesa Biotech Reports Fiscal Year 2025 Results
December 12, 2025
Edesa Biotech Announces Upcoming Conference Schedule
October 31, 2025
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
October 28, 2025
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
August 8, 2025
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
May 14, 2025
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
April 28, 2025
Edesa Biotech Announces Chief Financial Officer Transition
April 4, 2025
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
February 13, 2025
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
February 12, 2025
Edesa Biotech Reports Fiscal Year 2024 Results
December 12, 2024
Edesa Biotech : Founder Makes Strategic Investment in the Company Form 8 K
October 31, 2024
Edesa Biotech’s Founder Makes Strategic Investment in the Company
October 31, 2024
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
August 12, 2024
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
June 23, 2024
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
May 9, 2024
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
February 8, 2024
Edesa Biotech Reports Fiscal Year 2023 Results
December 14, 2023
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
November 19, 2023
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
October 11, 2023
Edesa Biotech Announces One-for-Seven Reverse Share Split
October 9, 2023
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
September 27, 2023
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
August 8, 2023
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
June 27, 2023
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
June 26, 2023
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
May 10, 2023
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
March 14, 2023
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
February 9, 2023
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
January 31, 2023
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
January 16, 2023
Edesa Biotech Reports Fiscal Year 2022 Results
December 15, 2022
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
November 2, 2022
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
September 29, 2022
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
September 6, 2022
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
August 11, 2022
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
May 23, 2022
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
May 12, 2022
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
April 27, 2022
Edesa Biotech Appoints Strategy Expert to Board of Directors
March 28, 2022
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
March 23, 2022